These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17188957)

  • 1. Hepatitis C: a new horizon.
    Chang KM
    Gastroenterology; 2006 Dec; 131(6):1667-8. PubMed ID: 17188957
    [No Abstract]   [Full Text] [Related]  

  • 2. [The recent progress on experimental models and molecular virology of hepatitis C virus].
    Zhong J
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):494-6. PubMed ID: 19912681
    [No Abstract]   [Full Text] [Related]  

  • 3. Experimental models for hepatitis C viral infection.
    Boonstra A; van der Laan LJ; Vanwolleghem T; Janssen HL
    Hepatology; 2009 Nov; 50(5):1646-55. PubMed ID: 19670425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment and vaccination for hepatitis C: present and future.
    Jawaid A; Khuwaja AK
    J Ayub Med Coll Abbottabad; 2008; 20(1):129-33. PubMed ID: 19024206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HCV research and anti-HCV drug discovery: toward the next generation.
    Wakita T
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1196-9. PubMed ID: 17905463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus virology and new treatment targets.
    Meier V; Ramadori G
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The hepatitis C virus life cycle as a target for new antiviral therapies.
    Pawlotsky JM; Chevaliez S; McHutchison JG
    Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice.
    McHutchison JG; Bartenschlager R; Patel K; Pawlotsky JM
    J Hepatol; 2006 Feb; 44(2):411-21. PubMed ID: 16364491
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation systems for anti-HCV drugs.
    Moriishi K; Matsuura Y
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1213-21. PubMed ID: 17720275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical consequences of hepatitis C virus quasispecies for target-specific antivirals.
    Fanning LJ
    J Infect Dis; 2008 Sep; 198(6):797-9. PubMed ID: 18637751
    [No Abstract]   [Full Text] [Related]  

  • 11. [Subgenomic replications of hepatitis C virus (HCV): new possibilities for hepatitis C prophylaxis and treatment].
    Puig-Basagoiti F; Sáiz JC
    Gastroenterol Hepatol; 2001 Dec; 24(10):506-10. PubMed ID: 11730621
    [No Abstract]   [Full Text] [Related]  

  • 12. Cyclic monophosphate prodrugs of base-modified 2'-C-methyl ribonucleosides as potent inhibitors of hepatitis C virus RNA replication.
    Gunic E; Girardet JL; Ramasamy K; Stoisavljevic-Petkov V; Chow S; Yeh LT; Hamatake RK; Raney A; Hong Z
    Bioorg Med Chem Lett; 2007 May; 17(9):2452-5. PubMed ID: 17331721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Worth the wait. New, more effective therapies for hepatitis C are on the way.
    Learned J
    Posit Aware; 2011; 23(1):15-8. PubMed ID: 21314021
    [No Abstract]   [Full Text] [Related]  

  • 14. Tailoring antiviral therapy in hepatitis C.
    Davis GL
    Hepatology; 2006 May; 43(5):909-11. PubMed ID: 16628667
    [No Abstract]   [Full Text] [Related]  

  • 15. Interfering with interferon: re-igniting the debate on calcineurin inhibitor choice and antiviral therapy for hepatitis C virus recurrence.
    Watashi K; Metselaar HJ; van der Laan LJ
    Liver Transpl; 2008 Mar; 14(3):265-7. PubMed ID: 18306373
    [No Abstract]   [Full Text] [Related]  

  • 16. New therapeutic prospects in HCV treatment.
    Almasio PL; Ingrassia D; Vergara B; Filosto S
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):775-9. PubMed ID: 19053890
    [No Abstract]   [Full Text] [Related]  

  • 17. Transgenic models for Hepatitis C virus pathogenesis.
    Fimia GM; Tripodi M; Alonzi T
    Cell Death Differ; 2003 Jan; 10 Suppl 1():S16-8. PubMed ID: 12655340
    [No Abstract]   [Full Text] [Related]  

  • 18. Genotype III - HCV infection.
    Amarapurkar DN; Choksi M
    Trop Gastroenterol; 2007; 28(2):58-63. PubMed ID: 18050840
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatitis C virus genetic variability in patients undergoing antiviral therapy.
    Cristina J; del Pilar Moreno M; Moratorio G
    Virus Res; 2007 Aug; 127(2):185-94. PubMed ID: 17449128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV.
    Meuleman P; Leroux-Roels G
    Antiviral Res; 2008 Dec; 80(3):231-8. PubMed ID: 18706933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.